3900 – Anti-ASGPR

Intended Purpose

The Anti-ASGPR is a semi-quantitative immunoassay for the determination of IgG antibodies against asialoglycoprotein receptor (ASGPR) in human serum. The Anti-ASGPR is intended as an aid in the diagnosis of systemic liver autoimmune disorders in conjunction with other clinical and laboratory findings. It provides reliable detection of ASGPR antibodies, which are clinically relevant markers of autoimmune liver disease, including autoimmune hepatitis (AIH). The assay helps distinguish autoimmune liver disorders from viral, toxic, or other chronic inflammatory liver conditions. It can also be used to monitor disease progression and response to therapy, as antibody levels typically decline with effective treatment. This information supports timely and accurate clinical decisions and can guide patient management and therapeutic interventions. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

The level of ASGPR, a liver specific membrane receptor playing a pivotal role in the endocytosis of glycoproteins from the blood, correlates with the severity of inflammatory liver disorders especially autoimmune hepatitis, and declines under therapy. Patients suffering from autoimmune hepatitis (AIH), one of the primary autoimmune liver disease, including primary biliary cirrhosis and primary sclerosing cholangitis, show a variety of autoantibodies. Determination of autoantibodies to ASGPR is used in the follow-up and differential diagnosis of toxic and other chronic inflammatory liver disorders, in that autoantibodies to this parameter, ASGPR, can be detected in sera of up to 76% of patients suffering from AIH.